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ORIGINAL CONTRIBUTIONS
 INTRODUCTION
 Patients with longstanding ulcerative colitis (UC) and Crohn’s 
disease (CD) with colonic involvement have an increased risk of 
developing colorectal cancer (CRC) ( 1,2 ). Endoscopic surveil-
lance aimed at the detection and treatment of dysplasia and CRC 
at an early stage is advocated to mitigate this risk, although solid 
evidence that this strategy is eff ective is lacking ( 3 ). Th e detec-
tion of neoplasia is challenging, as lesions containing neoplasia 
are oft en fl at or may not be endoscopically visible at all. Th ere-
fore, until recently, surveillance guidelines recommended taking 
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Chromoendoscopy for Surveillance in IBD
multiple random biopsies throughout the entire colon, although 
40 to 50 biopsies are needed to achieve an acceptable accuracy for 
detecting neoplasia ( 4,5 ). Moreover, the neoplasia yield of these 
random biopsies is disappointingly low ( 6 ). In addition, recently 
published studies show that almost all neoplastic lesions can be 
identifi ed endoscopically nowadays, casting further doubt on the 
practice of taking multiple random biopsies for surveillance pur-
poses ( 6–8 ).
 Several randomized trials reported that chromoendoscopy using 
indigo carmine or methylene blue can increase the neoplasia detec-
tion rate substantially compared with white light endoscopy with ran-
dom biopsy sampling (WLE) ( 9–12 ). Th ese fi ndings have prompted 
the British Society of Gastroenterology and American Gastroentero-
logical Association to advocate chromoendoscopy as the method 
of choice for CRC surveillance in their updated guidelines ( 13,14 ). 
Whether the broad implementation of chromoendoscopy in clini-
cal practice indeed increases the neoplasia detection rate compared 
with WLE is currently unknown. Th e aim of this study was therefore 
to compare the neoplasia detection rate of colonoscopies performed 
using chromoendoscopy with procedures performed with WLE.
 METHODS
 Patients
 Patients with a diagnosis of CD or UC were identifi ed in three 
referral centers using the diagnosis treatment combinations for 
infl ammatory bowel disease (IBD). Diagnosis treatment combi-
nations are based on the International Classifi cation of Disease, 
9th Revision, and can be considered the Dutch version of the 
diagnosis-related groups that are used in other countries.
 Th e medical records and endoscopy reports were reviewed to 
establish whether patients had a valid indication for CRC sur-
veillance, that is, patients with a disease duration of ≥8 years and 
cumulative colonic involvement of at least left -sided colitis (UC 
and IBD-unclassifi ed patients) or >30% of the colonic mucosa (CD 
patients). In addition, patients with colitis and primary sclerosing 
cholangitis were eligible as soon as the combination of these diag-
noses was established.
 Th e medical records were also reviewed to obtain the patients’ 
demographics, date of IBD diagnosis, type of IBD, disease extent 
before the start of surveillance, and family history of CRC.
 Details about the family history of CRC were obtained from a 
questionnaire as part of an observational cohort study for the sub-
group of patients who underwent chromoendoscopy.
 Surveillance colonoscopies
 All surveillance colonoscopies performed between January 2000 
and November 2013 in patients with a valid indication for surveil-
lance were collected. Colonoscopies were classifi ed as a surveil-
lance procedure when this was explicitly stated as the indication 
for the colonoscopy and when either random biopsies were taken 
or chromoendoscopy was performed.
 At the start of the study period, the three centers performed 
surveillance employing WLE with targeted biopsies of suspicious 
lesions in combination with four quadrant random biopsies every 
10 cm throughout the entire colon, in accordance with the inter-
national guidelines (WLE group) ( 4,5 ). In recent years, all cent-
ers adopted pancolonic chromoendoscopy with spraying of either 
0.3% indigo carmine or 0.1% methylene blue and targeted biopsies 
of suspicious lesions as the preferred surveillance method (chro-
moendoscopy group). Dye was applied using a spray catheter 
(Olympus PW-205V, Olympus Europe, Hamburg, Germany) one 
colonic segment at a time during extubation. Upon reintroduction, 
excess dye was suctioned of and during the second withdrawal the 
colonic mucosa was inspected.
 Endoscopists received no specifi c training for the technique of 
chromoendoscopy before its implementation, although each sur-
veillance procedure during the study period was performed by or 
under close supervision of gastroenterologists with extensive expe-
rience in dysplasia surveillance in IBD. Each surveillance colonos-
copy was included in the chromoendoscopy or the WLE group 
based on the method used as described in the endoscopy report. 
As this was a retrospective analysis over a 13-year period, multiple 
surveillance colonoscopies per patient were performed and there-
fore patients could be included in the WLE group as well as in the 
chromoendoscopy group.
 Procedures in which bowel preparation was deemed inadequate 
by the endoscopist or in which the cecum was not reached were 
excluded. Surveillance procedures that were aborted because of the 
presence of severe infl ammation were excluded as well. Th e par-
ticipating centers employed the British Society of Gastroenterol-
ogy guidelines published in 2002 to schedule the next surveillance 
procedure throughout the study period ( 5 ).
 Neoplasia
 Th e size, location, and endoscopic description of all lesions sus-
pected of containing neoplasia that were biopsied or removed 
endoscopically or surgically were recorded. Lesions were classi-
fi ed as nonneoplastic, low-grade dysplasia (LGD), high-grade 
dysplasia, or CRC based on the pathology report. Discrete soli-
tary sessile or pedunculated polyps resembling sporadic adeno-
mas and showing adenomatous tissue on histology were classifi ed 
as adenomas, whereas all other endoscopic abnormalities (i.e., 
plaque-like lesions, irregular masses) containing neoplasia were 
classifi ed as nonadenoma-like masses. In the WLE group, both 
the total number of random biopsies and the presence of neopla-
sia in these biopsies were recorded.
 Comparison between chromoendoscopy and WLE procedures
 Th e percentage of colonoscopies with neoplasia (neoplasia yield) 
was compared between all procedures performed with chromoen-
doscopy and those performed with WLE. In case of the WLE 
group, this comprised neoplasia in targeted as well as random 
biopsy samples. Th e total number of endoscopically visible lesions 
containing neoplasia was also compared between both groups.
 In the subgroup of patients in whom a WLE procedure was 
followed by a chromoendoscopy procedure during the study 
period, a direct comparison of the neoplasia detection rate between 
both surveillance methods was made within the same patient. As 
multiple consecutive surveillance procedures might decrease the 
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neoplasia yield of later colonoscopies, the same comparison was 
made between all patients in whom two subsequent WLE proce-
dures were performed as a reference.
 Statistics
 Baseline characteristics of the chromoendoscopy and WLE 
groups were compared using Pearson’s χ 2 analysis for categori-
cal variables and Student’s  t -test or Mann–Whitney  U -test for 
continuous variables, depending on whether data were normally 
distributed. Th e percentage of colonoscopies with neoplasia was 
compared between the chromoendoscopy and WLE groups using 
Pearson’s χ 2 analysis.
 Th e comparison between the neoplasia detection rate of chro-
moendoscopy and WLE within the same patients was made using 
the McNemar test. A  P value of <0.05 was considered statistically 
signifi cant. Statistical analysis was performed using SPSS version 
20 (Chicago, IL) for Windows.
 RESULTS
 In total, 937 patients (35% CD and 65% UC or IBD-unclassifi ed) 
underwent 2,242 surveillance colonoscopies during the study 
period. Chromoendoscopy was performed in 440 procedures in 
401 patients, whereas WLE was performed in 1,802 procedures 
in 772 patients ( Figure 1 ). Th e percentage of patients excluded 
because of inadequate bowel preparation was similar between the 
WLE and chromoendoscopy groups (15% vs. 12% respectively, 
 P =0.25). Baseline characteristics are shown in  Table 1 . A sub-
group of 236 patients underwent WLE as well as chromoendos-
copy during the study period. Th e number of CD patients with 
extensive colitis and the number of patients with a fi rst-degree 
relative diagnosed with CRC were signifi cantly higher in the chro-
moendoscopy group (66% vs. 51% and 16% vs. 4%, both  P <0.01, 
 Table 1 ). Th e diff erence in the percentage of patients with a posi-
tive family history of CRC could be explained by missing data in 
the WLE group, as the diff erence was no longer signifi cant aft er 
excluding patients with missing data (22% vs. 24%,  P =0.72). Fur-
thermore, the mean interval between the prior “pre-study” sur-
veillance colonoscopy and the chromoendoscopy procedure was 
signifi cantly longer compared with the surveillance interval in the 
WLE group (2.8 compared with 2.4 years,  P =0.01). Th ere were no 
signifi cant diff erences between the chromoendoscopy and WLE 
group with regard to other established risk factors for IBD-asso-
ciated CRC ( Table 1 ).
 Neoplasia detection rate
 In total, neoplasia was detected in 237 surveillance colonoscopies 
(11%) during the study period. LGD was detected in 227 proce-
dures (10%), high-grade dysplasia in 6 procedures (0.3%), and CRC 
in 4 procedures (0.2%). Th e overall neoplasia detection rate was 
comparable between the three centers (11% vs. 9% vs. 11% respec-
tively,  P =0.45). When surveillance colonoscopies were reviewed in 
chronological order, the neoplasia detection rate remained stable 
over time ( Figure 2 ). Th e number of surveillance procedures that 
each patient underwent had no eff ect on the neoplasia detection 
rate. In 9% of cases, dysplasia was detected during the fi rst proce-
dure that was comparable to the detection rate in the second (9%), 
third (15%), and fourth (10%) surveillance colonoscopies among 
the patients who underwent multiple consecutive surveillance pro-
cedures ( P =0.10,  Figure 3 ).
 Neoplasia detection per surveillance method
 Neoplasia was detected in 48 out of 440 surveillance procedures 
performed with chromoendoscopy (11%, 95% confi dence interval 
(CI) 8–14%) and in 189 of the 1,802 procedures performed with 
WLE (10%, 95% CI 9–12%,  P =0.80). Th e cumulative neoplasia 
detection rate over time for each surveillance technique is shown 
in  Figure 4 . If the 236 patients who underwent both chromoen-
doscopy and WLE were excluded from the analysis, the neoplasia 
detection rate remained comparable between the chromoendos-
copy group (10%, 95% CI 6–14%) and the WLE group (11%, 95% 
CI 9–13%  P =0.65). Th e similarity in neoplasia detection between 
chromoendoscopy and WLE procedures was observed in all three 
centers (11% vs. 11%,  P =0.91, 8% vs. 9%,  P =0.65, 12% vs. 10%, 
 P =0.60 respectively).
 Comparison between chromoendoscopy and WLE procedures 
within the same patients
 Of the 236 patients who underwent both chromoendoscopy 
and WLE during the study period, 5 were excluded because 
they underwent WLE aft er chromoendoscopy. Neoplasia was 
detected in 31 (13%, 95% CI 9–18%) of the WLE procedures and 
in 30 (13%, 95% CI 9–18%) of the chromoendoscopy procedures 
( P =1.0). As a reference, 661 paired consecutive WLE procedures 
were available, of which the neoplasia detection rate was 8% (95% 
CI 6–10%) in the fi rst procedure compared with 11% (95% CI 
9–13%) in the following procedure ( P =0.05).
 Neoplasia characteristics per surveillance method
 In the chromoendoscopy group, targeted biopsies were sampled 
from 546 lesions (mean 1.2 per procedure) that was signifi cantly 
higher than the 1,069 lesions (mean 0.6 per procedure) biopsied 
in the WLE group ( P <0.01,  Table 2 ). Th e targeted biopsies in the 
chromoendoscopy group identifi ed neoplasia in 48 procedures 
(11%), similar to the 158 procedures (9%) with neoplasia identi-
fi ed with targeted biopsies in the WLE group ( P =0.19). Th e num-
ber of lesions with neoplasia was also comparable between the 
chromoendoscopy and WLE groups ( P =0.30,  Table 2 ).
 Th e 51,602 random biopsies sampled in the WLE group yielded 
an additional 31 procedures (1%) in which neoplasia was detected. 
In all cases, this was found to be LGD.
 Learning curve
 Two endoscopists performed at least 50 consecutive surveillance 
colonoscopies with chromoendoscopy allowing analysis of a 
potential learning curve for this technique. Th e neoplasia detec-
tion rate when procedures are placed in chronological order for 
both endoscopists is shown in  Figure 5 . Th e neoplasia detection 
rate increased from 5 to 16% for one endoscopist ( P =0.14), but 
decreased from 17 to 8% for the second endoscopist ( P =0.09) 
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when the fi rst 50% of procedures were compared with the second 
50% of procedures.
 DISCUSSION
 Th is large retrospective study showed that the implementation of 
chromoendoscopy with targeted biopsies as the preferred surveil-
lance method did not result in an increased neoplasia detection 
rate as compared with WLE with random biopsies.
 Th is fi nding is in contrast with several controlled trials that 
showed a substantial increase in neoplasia detection using chro-
moendoscopy compared with WLE ( 9–12 ). Kiesslich  et al. ( 10,12 ) 
reported an impressive increase of dysplasia yield using chromoen-
doscopy as compared with WLE from 6 to 15% (combined data 
from 2 randomized controlled trials). Two other studies employing 
a back-to-back study design reported that among 202 procedures, 
the second withdrawal using chromoendoscopy increased the 
neoplasia detection rate from 7 to 13% ( 9,11 ). As dye spraying can-
not be undone, the two back-to-back studies could not perform 
WLE aft er chromoendoscopy, and this may have overestimated 
the additional neoplasia yield of chromoendoscopy in these par-
ticular studies. Studies in non-IBD patients using a back-to-back 
design have shown that the second colonoscopy, even when using 
standard WLE colonoscopy in both cases, increases the adenoma 
detection rate substantially ( 15 ). It is therefore conceivable that 
the same phenomenon could have resulted in higher yields in the 
second procedure in these colitis studies as well. Furthermore, 
the endoscopist cannot be blinded for the surveillance method. 
It could be that the expectation that chromoendoscopy performs 
better introduced a bias, despite randomization.
 Th e combined neoplasia detection rate using WLE from the ran-
domized trials and back-to-back studies was substantially lower 
than the rate in our study (7% vs. 10%), whereas the rate for chro-
moendoscopy was found to be higher compared with our results 
(14% vs. 11%). Th ese divergent outcomes may be because of several 
factors. First, the higher neoplasia detection rates in previous trials 
might be because of the fact that expert endoscopists with exten-
sive experience performed the chromoendoscopy procedures. 
Obviously, this would not explain the lower neoplasia yield of the 
WLE arm in the randomized controlled trials. As all three centers 
in our study started using chromoendoscopy without a training 
period before its implementation, the initial learning curve might 
have lowered the total neoplasia detection rate, especially com-
pared with the experts who performed chromoendoscopy in pre-
vious randomized trials. We investigated whether a learning curve 
was present in two endoscopists and found no signifi cant increase 
in neoplasia detection over time, suggesting there was no substan-
tial learning curve. Of note, the procedures in our cohort were per-
formed or supervised by endoscopists with extensive experience 
in surveillance colonoscopies for colitis, providing a near optimal 
setting for surveillance. Second, the absence of a strict protocol for 
surveillance colonoscopies in the three participating centers may 
























 Figure 1 .  Flowchart showing the patients included in each group. IBD, infl ammatory bowel disease; WLE, white light endoscopy with random biopsy sam-
pling.
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 Table 1 .  Baseline characteristics of the patients who underwent chromoendoscopy and WLE+random biopsies 
  Chromoendoscopy,  N  (%)  WLE+random biopsies,  N  (%)  P  value 
 Number of patients  401 (100)  772 (100)  NA 
 Male gender  203 (51)  399 (52)  0.71 
 Age (mean±s.d.)  49±12  49±13  0.80 
 Age at IBD diagnosis, years (mean±s.d.)  29±13  28±16  0.76 
 Duration of IBD, years (mean±s.d.)  20±12  20±15  0.95 
 IBD diagnosis 
  Ulcerative colitis  239 (60)  464 (60)  0.49 
  Distal splenic fl exure  85 (36)  175 (38)  0.77 
  Proximal splenic fl exure  141 (56)  270 (58)  
  Unknown  14 (6)  20 (4)  
  Crohn’s colitis  148 (37)  269 (35)  0.49 
  Segmental colitis <50%  47 (32)  114 (42)  <0.01 
  Segmental colitis >50%  98 (66)  137 (51)  
  Unknown  3 (2)  18 (7)  
  Indeterminate colitis  13 (3)  35 (5)  0.49 
  Segmental colitis <50%  3 (23)  18 (51)  0.15 
  Segmental colitis >50%  10 (77)  16 (46)  
  Unknown  0 (0)  1 (3)  
 Surveillance interval, years (mean±s.d.)  2.8±1.7  2.4±1.3  0.01 
 Concomitant diagnosis of PSC  40 (10)  68 (9)  0.51 
 First-degree relative with CRC diagnosis    <0.01 
 Yes  63 (16)  30 (4)  
 No  223 (55)  97 (13)  
 Unknown  115 (29)  645 (83)  
 Presence of postinfl ammatory polyps  80 (20)  166 (22)  0.36 
 CRC, colorectal cancer; IBD, infl ammatory bowel disease; NA, not applicable; PSC, primary sclerosing cholangitis; WLE, white light endoscopy with random biopsy sampling. 

































 Figure 2 .  Neoplasia detection rate over time when each surveillance colo-
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 Figure 3 .  Neoplasia detection rate among patients who underwent mul-
tiple surveillance colonoscopies during the study period. WLE, white light 
endoscopy with random biopsy sampling.
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have aff ected the quality of the procedures. As bowel preparation 
and the absence of infl ammation are paramount for the detection 
of subtle dysplastic lesions, especially when using chromoendos-
copy ( 16 ), the lack of a standardized approach might have resulted 
in the inclusion of low-quality procedures and missed lesions in 
our study. Again, this would not explain the relative low neopla-
sia yield in the randomized controlled trials and high neoplasia 
yield in our series in the WLE group. Th ird, as the study period 
spanned more than a decade, diff erent types of endoscopes were 
used over time, and this could have infl uenced neoplasia detection 
rates. Although data on the type and characteristics of the endo-
scopes used were not collected, the bulk of the chromoendoscopy 
procedures was performed in the past few years of the study period 
and therefore these procedures benefi tted from better endoscopes 
with a higher resolution. Th is could have led to a higher neoplasia 
detection rate in our chromoendoscopy group and a gradual over-
all increase of neoplasia yield in both the chromoendoscopy and 
WLE groups over time. However, the data from the current study 
do not support this assumption ( Figure 2 ).
 Th e retrospective nature of our study is an important limi-
tation, and this means our results should be interpreted with 
caution as this might have introduced several forms of bias. As our 
study covers a period of >10 years, it is conceivable that a change 
of the incidence of neoplasia has infl uenced our results. Sev-
eral epidemiological studies have shown that the risk of CRC is 
decreasing in IBD patients, possibly because of improved treatment 
and/or better implementation of endoscopic surveillance ( 17,18 ). 
By plotting each surveillance colonoscopy in chronological order, 
 Table 2 .  Neoplasia characteristics of the lesions detected in the chromoendoscopy and the WLE+random biopsy group 
  Chromoendoscopy  WLE+random biopsies  P  value 
 Number of colonoscopies  440  1,802  NA 
 Procedures with neoplasia (%)  48 (11)  189 (10)  0.80 
 Targeted biopsies  48 (11)  158 (9)  0.19 
 Random biopsies  NA  31 (1)  NA 
 Total number of lesions detected (mean±s.d.)  546 (1.2±1.5)  1,069 (0.6±1.2)  <0.01 
 Total number of targeted biopsies (mean±s.d.)  1,027 (3±3)  2,592 (1±3)  <0.01 
 Containing neoplasia (%)  114 (11)  714 (28)  
 Total number of random biopsies (mean±s.d.)  NA  51,602 (29±9)  NA 
 Lesions containing neoplasia (mean±s.d.)  59 (0.13±0.47)  211 (0.12±0.44)  0.30 
 Adenoma  53  185  0.15 
 Nonadenomatous lesion  6  16  0.24 
 HGD  0  6  0.23 
 CRC  0  4  0.32 
 Size of the lesions with neoplasia median (range)  4 (1–30)  3 (1–50)  0.41 
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 Figure 5 .  Neoplasia detection rate over time for chromoendoscopies 































0 200 400 600 800 1,000
Number of colonoscopies
1,200 1,400 1,600 1,800
Chromoendoscopy
WLE + random biopsies
 Figure 4 .  Neoplasia detection rate over time for chromoendoscopy and 
white light endoscopy with random biopsy sampling (WLE).
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taking additional random biopsies, rendering chromoendoscopy 
as a fl agging tool redundant in the near future.
 In conclusion, we did not fi nd an increase in neoplasia detection 
aft er the implementation of chromoendoscopy as compared with 
the conventional WLE plus random biopsies protocol. Although 
more studies are needed to confi rm this and our results could 
be biased because of the retrospective nature of our study, these 
results cast doubt on the standard use of chromoendoscopy as the 
preferred surveillance tool in IBD.
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 Study Highlights
 WHAT IS CURRENT KNOWLEDGE 
 ✓  The risk of colorectal cancer in ulcerative colitis and 
Crohn’s colitis is increased and therefore guidelines recom-
mend colonoscopic surveillance in these patients. 
 ✓  Previously, surveillance was performed with white light 
endoscopy combined with the sampling of four random 
biopsies every 10 cm throughout the colon. 
 ✓  Pancolonic spraying of the colonic mucosa with indigo 
carmine or methylene blue (chromoendoscopy) has been 
found to signifi cantly increase the dysplasia detection rate 
in several controlled trials. 
 WHAT IS NEW HERE 
 ✓  Implementing chromoendoscopy as the preferred surveil-
lance method in recent years did not improve dysplasia 
detection rates as compared with white light endoscopy in 
a large “real-life” cohort. 
 ✓  Although this is a retrospective, nonrandomized study, 
these results cast doubt on the use of chromoendoscopy as 
the preferred surveillance technique in clinical practice. 
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we found that the neoplasia detection rate remained remarkably 
stable throughout the study period, suggesting this did not infl u-
ence our results ( Figure 2 ). Th eoretically, however, the decreased 
incidence of neoplasia in IBD over time could have been balanced 
out by the increased neoplasia yield using chromoendoscopy and/
or better endoscopes.
 Th e fact that this study was retrospective and not randomized 
might well have resulted in a diff erence in patient characteristics 
between the chromoendoscopy and WLE groups. We indeed found 
that the percentage of CD patients with extensive colitis and patients 
with a positive family history for CRC was higher in the chromoen-
doscopy group. As these are both risk factors for CRC, these dif-
ferences should have caused a higher rather than a lower dysplasia 
detection rate. Th e interval between the last “pre-study” surveillance 
colonoscopy and the procedures performed with chromoendos-
copy was also signifi cantly longer compared with the surveillance 
intervals in the WLE group. Again, as a longer surveillance interval 
theoretically results in more time for neoplasia to develop, this bias 
would only increase the neoplasia detection rate. Of course, some 
level of residual confounding is undoubtedly present.
 Despite the fact that there were no signifi cant diff erences in both 
the number of lesions or procedures with neoplasia between the 
chromoendoscopy and WLE groups, it is conceivable that chro-
moendoscopy aids in the detection of more subtle, small, and 
fl at dysplastic lesions ( 10 ). Th e fact that the size of the dysplas-
tic lesions was comparable in both groups does not support this 
notion however.
 Another issue that cannot be addressed by the current study 
design is the clinical relevance of the neoplastic lesions detected by 
both surveillance techniques. Th e ultimate goal of surveillance is 
to detect and treat dysplastic lesions that would otherwise progress 
to CRC and thereby decrease CRC-related mortality. Especially for 
LGD detected in random biopsies, there has been much debate on 
whether this fi nding is clinically relevant. Although some studies 
showed that between 37 and 53% of patients with confi rmed LGD 
detected in random biopsies progress to high-grade dysplasia or 
CRC during follow-up ( 19,20 ), others have reported that the inci-
dence of dysplasia in random biopsies is extremely low and that this 
usually has no consequences for the follow-up strategy ( 6 ). Th e same 
holds true for the additional neoplasia detected with chromoendos-
copy compared with conventional WLE. It has been suggested that 
these lesions are oft en small and fl at, but there are no follow-up stud-
ies on the progression rates to advanced neoplasia of these lesions.
 If future prospective studies will confi rm our results, the ques-
tion arises of what the role of chromoendoscopy should be in the 
setting of CRC surveillance in IBD patients. Chromoendoscopy 
was initially commended for its superior neoplasia detection, 
but it may also be less costly than WLE plus random biopsies as 
well that in itself could be an incentive to prefer chromoendos-
copy ( 21 ). Furthermore, chromoendoscopy might aid in assess-
ing the pit pattern of lesions and thereby aiding the diff erentiation 
between neoplastic and nonneoplastic lesions. On the other hand, 
it is conceivable that the targeted biopsies guided by the pre-
sent, state-of-the-art, high-defi nition colonoscopes can provide 
the same neoplasia detection rates as chromoendoscopy without 
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